Related Experiment Video
Updated: Feb 13, 2026

Extended Live Imaging of Female Drosophila melanogaster Germline Stem Cell Niches
Published on: December 20, 2024
Pharmacological inhibition of EZH2 disrupts the female germline epigenome
Lexie Prokopuk1,2, Kirsten Hogg1,2, Patrick S Western1,2
11Centre for Reproductive Health, Hudson Institute of Medical Research, Clayton, Victoria 3168 Australia.
Background:
Recently discovered drugs that target epigenetic modifying complexes are providing new treatment options for a range of cancers that affect patients of reproductive age. Although these drugs provide new therapies, it is likely that they will also affect epigenetic programming in sperm and oocytes. A promising target is Enhancer of Zeste 2 (EZH2), which establishes the essential epigenetic modification, H3K27me3, during development.
Results:
In this study, we demonstrate that inhibition of EZH1/2 with the clinically relevant drug, tazemetostat, severely depletes H3K27me3 in growing oocytes of adult female mice. Moreover, EZH2 inhibition depleted H3K27me3 in primary oocytes and in fetal oocytes undergoing epigenetic reprogramming. Surprisingly, once depleted, H3K27me3 failed to recover in growing oocytes or in fetal oocytes.
Conclusion:
Together, these data demonstrate that drugs targeting EZH2 significantly affect the germline epigenome and, based on genetic models with oocyte-specific loss of EZH2 function, are likely to affect outcomes in offspring.
Insights
Cancer drugs targeting EZH2 (Enhancer of Zeste 2) significantly deplete a key epigenetic mark, H3K27me3, in mouse oocytes. This depletion is long-lasting and may impact offspring development.
Area of Science:
- Reproductive biology
- Epigenetics
- Developmental biology
Background:
- Epigenetic modifying complexes are targets for novel cancer therapies.
- Drugs targeting these complexes may impact germline epigenetic programming.
- Enhancer of Zeste 2 (EZH2) is crucial for establishing H3K27me3 during development.
Purpose of the Study:
- To investigate the effects of EZH1/2 inhibition on H3K27me3 in mouse oocytes.
- To determine if H3K27me3 levels recover after drug treatment.
Main Methods:
- Treatment of adult female mice with tazemetostat, a clinically relevant EZH1/2 inhibitor.
- Analysis of H3K27me3 levels in growing, primary, and fetal oocytes.
- Assessment of H3K27me3 recovery post-inhibition.
Main Results:
- Tazemetostat severely depleted H3K27me3 in growing oocytes.
- H3K27me3 was also depleted in primary and fetal oocytes.
- H3K27me3 failed to recover in oocytes after EZH1/2 inhibition.
Conclusions:
- Drugs targeting EZH2 significantly impact the germline epigenome.
- Oocyte-specific loss of EZH2 function suggests potential effects on offspring outcomes.
- Further research is needed to understand the long-term consequences for reproductive health.
Related Concept Videos
Feedback Inhibition
Infertility in Females
Endometriosis, a condition characterized by abnormal growth of...
External Female Genitals
Disorders of the Female Reproductive System
Enzyme Inhibition
Inhibition of Cdk Activity

